TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03959592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein, zeaxanthin and mesozeaxanthin
Description: The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
Study: NCT06158308

Intervention type: PROCEDURE
Intervention: Laproscopic Appendicectomy
Description: A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.

Intervention type: PROCEDURE
Intervention: Open Appendicectomy
Description: A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
Study: NCT02827942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg bid
Description: Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan 20 mg bid
Description: Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg tid
Description: Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 750 mg bid
Description: Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 200 mg bid
Description: Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 mg bid
Description: Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
Study: NCT02340520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Oral
Study: NCT00432510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study: NCT01290822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiVP
Description: Biventricular pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AAI Pacing
Description: Atrial pacing
Study: NCT03716622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: bismuth-furazolidone-containing quadruple regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: bismuth-clarithromycin-containing quadruple regimens
Study: NCT01261143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701
Description: tablet, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BK-C-0701
Description: tablet, 8 weeks
Study: NCT01946581

Intervention type: PROCEDURE
Intervention: Cataract Surgery
Study: NCT00089895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin)
Description: intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
Study: NCT03348475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binge Focused Therapy (BFT) Intervention
Description: The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
Study: NCT01698879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Cohort 1 version 1.0. GO: 6mg/m\^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m\^2, SC, days 0 to 7. GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO.
Study: NCT01128101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
Study: NCT03655912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red/green glasses
Description: The use of red/green glasses and electronic devices for two hours a day during 4 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Tablet
Description: The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
Study: NCT02892422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study
Study: NCT03740555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 single dose
Description: HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo single ascending doses , Intravenous route Single dose, matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 multiple ascending doses
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple ascending doses
Description: Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
Study: NCT02848365

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be done with any of these equipments
Study: NCT03917472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab
Description: Intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT04596709

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitalose
Description: dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isomaltulose
Description: dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: dissolved in water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose
Description: dissolved in water
Study: NCT02479698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic BK-specific Cytotoxic T-lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01190267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
Study: NCT02589249

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AyuFlex
Description: Active product

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AyuFlex
Description: Active product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03568682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling + urban gardening
Description: Peer nutritional counseling and urban gardens
Study: NCT03727126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic esophagectomy
Description: Removal of the esophagus and its draining lymph nodes using robotic surgical instruments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolaparoscopic esophagectomy
Description: Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
Study: NCT03727152

Intervention type: DRUG
Group type: OTHER
Intervention: generic single tablet TAF/FTC/DTG
Description: HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
Study: NCT01839617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early parenteral nutrition
Study: NCT00089895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous; delivery to match eptifibatide to maintain blind
Study: NCT04078035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-evaluative speech task
Description: 5-minute speech task designed to induce physiological arousal in a laboratory setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-evaluative speech task
Description: 5-minute speech task designed to induce physiological arousal in a laboratory setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control, Quiet Rest
Description: 5-minute quiet rest period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control, Quiet Rest
Description: 5-minute quiet rest period.
Study: NCT03835637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension
Study: NCT01839617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Late parenteral nutrition
Study: NCT02853669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Lumber Plexus Block
Description: (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adductor canal block
Description: ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
Study: NCT03250767

Intervention type: DEVICE
Intervention: Integra Titan Modular Shoulder System 2.5
Description: Primary Shoulder Joint Replacement
Study: NCT03841968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic needle tip positioning under ultrasound-guidance
Description: The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional long-axis view
Description: The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
Study: NCT00200109

Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital Nerve Stimulation
Description: Each group had a different plan

Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital Nerve Stimulation
Description: Each group had a different plan

Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital Nerve Stimulation
Description: Each group had a different plan

Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital Nerve Stimulation
Description: Each group had a different plan
Study: NCT03902717

Intervention type: PROCEDURE
Intervention: Minimally invasive cardiac surgery
Description: Patients will undergo minimally invasive cardiac surgery
Study: NCT00405522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg
Description: Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg
Description: Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Study: NCT03608657

Intervention type: DRUG
Intervention: Apremilast
Description: Apremilast
Study: NCT03933670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Ultrasound Fusion Guided Biopsy
Description: Undergo MR/US fusion-guided prostate biopsy
Study: NCT03128320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 1 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 1 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 1 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 5 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 5 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1193397
Description: Single dose of 5 mg BAY1193397 given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo given in the fasted state
Study: NCT00791661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1006
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-1006 in a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-1006 in a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to MK-1006 in a single oral dose
Study: NCT00658775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole sodium
Description: Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
Study: NCT01129349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
Study: NCT04017832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (oral semaglutide)
Description: Placebo tablet to be taken first thing in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: Placebo tablet to be taken 30 minutes after oral semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: Placebo tablet to be taken 30 minutes after oral semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (sitagliptin)
Description: Placebo tablet to be taken 30 minutes after oral semaglutide
Study: NCT03430401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual-based memory encoding
Description: It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic-based memory encoding
Description: It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stimulation
Description: The frequency, duration and the number of sessions will be consistent with the experimental interventions.
Study: NCT03192618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant transarterial chemoinfusion (TAI)
Description: transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
Description: oxaliplatin, calcium folinate, and 5-FU
Study: NCT03219359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Hematopoietic stem cell transplantation
Study: NCT03835637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-101
Description: Capsule or oral suspension
Study: NCT03219359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ \>20x104/ml then leukapheresis daily to collection goal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Day -6 to -3: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Day -3 to -1: 1 gram prior to each ATG dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)